Evidence map›Paper›PMID 42191125›Full record

ArticleHepatology (Baltimore, Md.)2026

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Virginia Hernandez-Gea, Valerie Paradis, Maha Guindi, Venancio A F Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A R de Freitas and 21 more

Abstract readConsensus Statement
In one paragraph

Article in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Virginia Hernandez-GeaBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Clínic Barcelona, FRCB-IDIBAPS (Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain.ORCID 0000-0001-7937-984
Valerie ParadisCentre de recherche sur l'inflammation, Université Paris-Cité, Inserm, UMR 1149, Paris, France.ORCID 0000-0003-3142-3762
Maha GuindiDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0002-4864-6498
Venancio A F AlvesDepartment of Pathology, University of São Paulo School of Medicine, CICAP, Pathology, Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brasil.ORCID 0000-0001-5285-4460
Amal AqulDepartment of Pediatrics, UT Southwestern Medical Center in Dallas/Children's Health, Dallas, Texas, USA.ORCID 0000-0003-4599-9746
Eira CerdaDepartment of Gastroenterology, Central Military Hospital, Mexico City, Mexico.ORCID 0000-0003-1288-888
Sarwa Darwish MuradDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Center, ERN RARE-LIVER Affiliated Center for Rare Vascular Disorders, Rotterdam, The Netherlands.ORCID 0000-0003-2804-1165
Prasenjit DasDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.ORCID 0000-0002-2420-8573
Angelo Di GiorgioPediatric Liver Service, Hospital Santa Maria Misericordia, University of Udine, Urdine, Italy.ORCID 0000-0003-0363-5565
Luiz A R de FreitasDepartment of Pathology, Faculty of Medicine of Bahia, Federal University of Bahia, Brazil. Gonçalo Moniz Institute of the Oswaldo Cruz Foundation, Bahia, Brazil.ORCID 0000-0001-5499-9858
Tassos GrammatikopoulosPediatric Liver, GI and Nutrition Centre and Mowat Labs, King's College Hospital NHS Trust, London, UK.ORCID 0000-0002-0174-4787
Kenichi HaradaHuman Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.ORCID 0000-0002-6451-0638
Nelia HernandezUnidad Académica Gastroenterología, Hospital de Clínicas, Facultad de Medicina, Udelar, Montevideo, Uruguay.ORCID 0000-0001-6816-3699
Samar H IbrahimDepartment of Pediatrics, Division of Pediatric Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-8470-8337
Sanjay KakarDepartment of Pathology, University of California, San Francisco, California, USA.ORCID 0000-0003-2526-4080
Saul KarpenDepartment of Pediatrics, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University, Richmond, Virginia, USA.ORCID 0000-0002-3379-7592
David E KleinerLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-3442-4453
Necati OrmeciInternal Medicine and Hepatogastroenterology Department, Istanbul Health and Technology University, Istanbul, Turkiye.ORCID 0000-0002-8909-2102
Xiaolong QiBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Clínic Barcelona, FRCB-IDIBAPS (Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain.ORCID 0000-0002-3559-5855
Puja SakhujaDepartment of Pathology, GB Pant Institute of Postgraduate Medical Education and Research, Delhi, India.ORCID 0000-0001-7286-5941
Maria Isabel SchinoniDivision of Gastrohepatology, Professor Edgard Santos University Hospital, Federal University of Bahia, Salvador, Bahia, Brazil.ORCID 0000-0001-9037-8127
Romil SaxenaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-1872-0431
Alexandre SayadiCentre de recherche sur l'inflammation, Université Paris-Cité, Inserm, UMR 1149, Paris, France.ORCID 0000-0003-4377-9926
Akash ShuklaDepartment of Hepatology, Sir HN Reliance Foundation Hospital, Mumbai, Maharashtra, India.ORCID 0000-0001-7718-9452
Dina G TiniakosTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-4657-7780
Elizabeth VernaTransplant Clinical Research Center, Columbia University, New York, New York, USA.ORCID 0000-0002-9658-3751
Kerry WongDepartment of Pediatrics, Division of Gastroenterology and Nutrition, University of Alberta, Edmonton, Alberta, Canada.
Laure ElkriefFaculté de médecine de Tours et Hôpital Trousseau, CHRU de Tours, Centre de Référence Constitutif des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Tours, France.ORCID 0000-0003-2843-1710
Christine SempouxInstitute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1375-3979
Theo HellerTranslational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2643-6289
Pierre-Emmanuel RautouCentre de recherche sur l'inflammation, Université Paris-Cité, Inserm, UMR 1149, Paris, France.ORCID 0000-0001-9567-1859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology-such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia-leading to substantial variability in diagnosis, reporting, and international research collaboration. Differences in guideline definitions from major societies (AASLD, EASL, and APASL), together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification. To address these challenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally harmonized and implementable diagnostic framework. Consensus was reached that the terms porto-sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF . The diagnosis was defined as fundamentally clinicopathological, requiring integrated assessment. Core principles include the need for a high-quality liver biopsy (≥10 mm), mandatory exclusion of cirrhosis, and systematic exclusion of specific alternative conditions. Importantly, the consensus recognizes that PSVD or NCPF may be diagnosed even without clinical portal hypertension and may coexist with other liver diseases, provided cirrhosis is excluded. Standardized major and minor histologic criteria were developed collaboratively by expert pathologists and externally validated. Features of portal hypertension were harmonized into specific and nonspecific categories applicable to routine clinical practice. An integrated diagnostic scoring system incorporating histology, clinical features, associated conditions, and concommitant etiologies was developed and validated using the Delphi method. This consensus provides the first internationally endorsed, unified framework for the diagnosis of PSVD or NCPF. Its global implementation is expected to reduce diagnostic variability, improve comparability across regions, and facilitate the development of robust, internationally harmonized clinical and translational research cohorts.

Indexed as

Hypertension, PortalVascular DiseasesHumansIdiopathic Noncirrhotic Portal HypertensionTerminology as Topicidiopathic portal fibrosisnodular regenerative hyperplasianoncirrhotic portal hypertensionportal hypertensionportosinusoidal vascular disorder

Identifiers

PMID42191125
PMCPMC13374651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.